Iovance Biotherapeutics (STU:2LB) Beginning Cash Position : €211.83 Mil (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Iovance Biotherapeutics Beginning Cash Position?

Iovance Biotherapeutics's Beginning Cash Position for the quarter that ended in Sep. 2024 was €211.83 Mil.

Iovance Biotherapeutics's quarterly Beginning Cash Position declined from Mar. 2024 (€166.81 Mil) to Jun. 2024 (€130.64 Mil) but then increased from Jun. 2024 (€130.64 Mil) to Sep. 2024 (€211.83 Mil).

Iovance Biotherapeutics's annual Beginning Cash Position increased from Dec. 2021 (€64.48 Mil) to Dec. 2022 (€79.59 Mil) and increased from Dec. 2022 (€79.59 Mil) to Dec. 2023 (€218.40 Mil).

Iovance Biotherapeutics Beginning Cash Position Historical Data

The historical data trend for Iovance Biotherapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iovance Biotherapeutics Beginning Cash Position Chart

Iovance Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

73.94

15.96

64.48

79.59

218.40

Iovance Biotherapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Beginning Cash Position	Get a 7-Day Free Trial															277.76	306.42	166.81	130.64	211.83

Iovance Biotherapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Iovance Biotherapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Iovance Biotherapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Iovance Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iovance Biotherapeutics Inc (STU:2LB) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

IOVA:USA 0JDK:UK 2LB:Germany

Address

825 Industrial Road, Suite 400, San Carlos, CA, USA, 94070

Website

https://www.iovance.com

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Iovance Biotherapeutics Headlines

No Headlines